Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal for Immunotherapy of Cancer|April 11, 2025
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effectsMichela Capello, Angelica Sette, Theo Plantinga, et al.Cancer Discovery|July 7, 2021
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 KnockdownNabendu Pore, Song Wu, Nathan Standifer, et al.Cell|December 4, 2018
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK CellsPascale André, Caroline Denis, Caroline Soulas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell CarcinomaToni K Choueiri, Mayer N Fishman, Bernard Escudier, et al.Journal for Immunotherapy of Cancer|July 7, 2026
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphomaFarrukh T Awan, Joshua T Gamse, Marije B Overdijk, et al.The New England Journal of Medicine|June 5, 2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancerSuzanne L Topalian, F Stephen Hodi, Julie R Brahmer, et al.Cancer Discovery|February 17, 2022
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsAlexander Muik, Elena Garralda, Isil Altintas, et al.Cancer Research Communications|October 30, 2025
Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid TumorsKristoffer Staal Rohrberg, Juanita S Lopez, Mohammed M Milhem, et al.Pageof 4